

**APELLIS PHARMACEUTICALS, INC.**

6400 Westwind Way, Suite A  
Crestwood, KY 40014

November 6, 2017

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Apellis Pharmaceuticals, Inc.  
Registration Statement on Form S-1  
File No. 333-220941  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Apellis Pharmaceuticals, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-220941), as amended (the "Registration Statement"), so that it may become effective at 4:00 p.m. Eastern time on November 8, 2017, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

\* \* \* \*

Very truly yours,

**APELLIS PHARMACEUTICALS, INC.**

By: /s/ David Watson

Name: David Watson

Title: General Counsel

cc: Cedric Francois, *Apellis Pharmaceuticals, Inc.*  
Stuart M. Falber, *Wilmer Cutler Pickering Hale and Dorr LLP*  
Brent B. Siler, *Cooley LLP*  
Darren DeStefano, *Cooley LLP*  
Divakar Gupta, *Cooley LLP*  
Mark Ballantyne, *Cooley LLP*